Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | What to look forward to in GU cancers at ESMO 2024

Aristotelis Bamias • 13 Sep 2024
ESMO 2024
Bladder Cancer Genitourinary Cancer Kidney Cancer

Aristotelis Bamias, MD, PhD, University of Athens, Athens, Greece, shares his top picks in genitourinary cancers at ESMO 2024, including findings from the NIAGARA study (NCT03732677) of neoadjuvant immunotherapy, as well as updates from the use of belzutifan in kidney cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Aristotelis Bamias

Applying real-world treatment patterns in prostate cancer in Greece
1:37
Applying real-world treatment patterns in prostate cancer in Greece
Aristotelis Bamias • 13 Sep 2024
Evaluating futibatinib, EV and DV with pembrolizumab in urothelial carcinoma
3:43
Evaluating futibatinib, EV and DV with pembrolizumab in urothelial carcinoma
Aristotelis Bamias • 13 Sep 2024
IMvigor130: clinical implications and next steps
2:06
IMvigor130: clinical implications and next steps
Aristotelis Bamias • 18 Feb 2023
ASCO GU 2023: moving immunotherapy into the first-line setting for bladder cancer
1:12
ASCO GU 2023: moving immunotherapy into the first-line setting for bladder cancer
Aristotelis Bamias • 18 Feb 2023

Related Videos

Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
3:36
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
Tian Zhang • 1 Jun 2026
Drug repurposing and trial challenges in rare renal medullary carcinoma
3:11
Drug repurposing and trial challenges in rare renal medullary carcinoma
Pavlos Msaouel • 30 May 2026
The content of VJOncology is intended for healthcare professionals